Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RegenxbioFRA:RB0 -1.54%62 3-Year EBITDA Growth Rate is 23.00% as of Jun. 2026. GuruFocus rates FRA:RB0 with a GF Score™ of 62/100 and a GF Value™ of €13.24 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,127 Biotechnology companies, Regenxbio ranks better than 60.07% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 23.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Regenxbio was 23.00% per year. The lowest was -106.10% per year. And the median was -15.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Regenxbio 3-Year EBITDA Growth Rate Related Terms
FRA:RB0 vs CTNM, CRMD, AGMB: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Regenxbio's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenxbio 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regenxbio's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Regenxbio's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 23.00% mean?
Regenxbio (FRA:RB0) has a 3-Year EBITDA Growth Rate of 23.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Regenxbio and its competitors. According to the industry distribution chart, Regenxbio ranks #450 out of 1127 companies in the Biotechnology industry, placing it in the top 39.9%.
Is Regenxbio's 3-Year EBITDA Growth Rate too high?
Regenxbio's current 3-Year EBITDA Growth Rate is 23.00%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.80. Regenxbio's value of 23.00% is 55.4% above this industry median. Based on the distribution chart, Regenxbio ranks #450 out of 1127 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Regenxbio has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Regenxbio's 3-Year EBITDA Growth Rate compare to CTNM and CRMD?
According to the Biotechnology industry distribution chart, Regenxbio ranks #450 out of 1127 companies for 3-Year EBITDA Growth Rate. This puts Regenxbio in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.80. Regenxbio's value of 23.00% is 55.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.80, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regenxbio's current 3-Year EBITDA Growth Rate of 23.00% is 55.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Regenxbio and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regenxbio's current 3-Year EBITDA Growth Rate is 23.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenxbio stock overvalued right now?
Based on GuruFocus' analysis, Regenxbio (FRA:RB0) is currently considered Possible Value Trap. The stock's GF Value™ is €13.24, compared to a current price of €8.08 — trading 39% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 23.00% and 55.4% above the Biotechnology industry median of 14.80. Regenxbio's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Regenxbio (FRA:RB0), the current 3-Year EBITDA Growth Rate is 23.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regenxbio (FRA:RB0) Overvalued in 2026?
Based on GuruFocus' analysis, Regenxbio stock appears to be undervalued.
The current stock price of €8.08 is trading 39% below its estimated GF Value™ of €13.24.
GuruFocus considers Regenxbio to be Possible Value Trap.
Key valuation signals for FRA:RB0:
3-Year EBITDA Growth Rate: 23.00%
GF Value™: €13.24 vs. price of €8.08 (39% below fair value)
Industry Position: 55.4% above the Biotechnology median (#450 of 1127)
No single metric tells the full story. See the FRA:RB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
62GF Score
Get the complete analysis for FRA:RB0
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RB0 has been successfully added to your 
